Dimethyl fumarate for beta-cell preservation
Generic / repurposed
A repurposed oral immunomodulator best known as the multiple-sclerosis drug Tecfidera, now being tested in two recruiting Chinese studies: a randomized phase 3 trial in 90 adults with newly diagnosed T1D and a nonrandomized, open-label phase 2/3 trial in 96 adults. Neither has posted T1D efficacy results, so this remains a trial-watch entry rather than a treatment claim.
The scorecard
Both studies are designed around mixed-meal C-peptide AUC, but neither has posted type 1 diabetes efficacy results.[1]
Durability is unknown; the trial follows C-peptide after a 24-week intervention but has not reported.[1]
Dimethyl fumarate has an established MS safety label, but carries clinically important risks including lymphopenia and PML warnings, which matter when repurposed for early T1D.[3]
Both studies enroll adults aged 18-65 with residual beta-cell function; there are no pediatric, stage-1 or stage-2 prevention data.[2]
A randomized phase 3 trial and a separate open-label phase 2/3 trial are recruiting, but the T1D evidence base has not crossed from rationale to reported efficacy.[1]
The full picture
Dimethyl fumarate is interesting because it is oral, already manufactured, and immunomodulatory. But the T1D story is still almost entirely prospective: clinical trials are asking whether it can preserve endogenous insulin production after diagnosis, and the answer is not yet known.
The two studies should not be blurred together. NCT07258394 is a randomized, placebo-controlled phase 3 study planning 90 adults with newly diagnosed T1D. NCT07548996 is a separate nonrandomized, open-label phase 2/3 study planning 96 adults: dimethyl fumarate is added to standard insulin and compared with standard insulin alone. In that second study the dose rises from 120 mg twice daily to 240 mg twice daily after seven days, with 24 weeks of treatment and 52 weeks of follow-up. Its primary endpoint is baseline-adjusted two-hour mixed-meal C-peptide AUC at week 48.
Repurposing shortens the drug-development learning curve, but it does not make the T1D benefit known. Tecfidera's established label also brings relevant risks, including lymphopenia and progressive multifocal leukoencephalopathy warnings. Until a controlled T1D result is posted, an existing MS approval is safety and manufacturing context—not evidence that dimethyl fumarate preserves beta cells in T1D.
Coming soon
ETA · Randomized phase 3 and open-label phase 2/3 studies recruiting; both list primary completion in December 2028
- →Randomized phase 3 C-peptide readout in new-onset adult T1D · primary completion estimated December 2028
- →Open-label phase 2/3 comparison of dimethyl fumarate plus insulin versus standard insulin therapy · primary completion estimated December 2028
Sources
- [1]Clinical Study for Dimethyl Fumarate in Preserving Islet Beta-Cell Function in Type 1 Diabetes Mellitus · registry · 2026-03-05
- [2]Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes · registry · 2026-04-23 — Revision posted 21 July 2026 confirms recruiting status and an actual 27 April 2026 start. This is a nonrandomized phase 2/3 active-comparator study, not a second randomized phase 3 trial.
- [3]TECFIDERA (dimethyl fumarate) prescribing information · regulatory · 2024-01-01